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ABSTRACT 
 
Objectives: To investigate the effect of withdrawal of Fall-Risk-Increasing-Drugs (FRIDs) 
versus ‘care as usual’ on reducing falls in community-dwelling older fallers. 
Design: Randomized multicenter trial. 
Participants: 612 older adults who visited an Emergency Department (ED) because of a fall. 
Interventions: Systematic FRIDs assessment combined with FRIDs-withdrawal or 
modification, when safely possible. 
Main Outcomes and Measures: Primary outcome was time to the first self-reported fall. 
Secondary outcomes were time to the second self-reported fall and to falls requiring a general 
practitioner (GP)-consultation or ED visit. Intention-to-treat (primary) and a per-protocol 
(secondary) analysis were conducted. The hazard ratios for time-to-fall were calculated using 
a Cox-regression model. Differences in cumulative incidence of falls were analysed using 
Poisson regression. 
Results: During 12 months follow-up, 91 (34%) control and 115 (37%) intervention 
participants experienced a fall; 35% of all attempted interventions failed, either due to non-
compliance or recurrence of the initial indication for prescribing or additional medication for 
newly diagnosed disorders; compared to baseline, the overall percentage of users of ≥3 
FRIDs at 12 months did not change in either the intervention or the control group. Our 
intervention approach did not have a significant effect on time to first fall (hazard ratio [HR] 
1.17; 95% confidence interval [CI] 0.89-1.54), time to second fall (1.19; 0.78-1.82), time to 
first fall-related GP-consultation (0.66; 0.42-1.06), or time to first fall-related ED-visit (0.85; 
0.43-1.68).  
Conclusions and Relevance: In this population of complex multimorbid patients visiting an 
ED because of a fall our single intervention approach of FRIDs-withdrawal was not effective 
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in reducing falls. Non-compliance was a significant factor; this may have affected the 
outcomes negatively, but also mirrors clinical practice. 
 
Keywords: RCT, FRID, withdrawal, falls 
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INTRODUCTION  
 
Falls affect a large proportion of persons aged 65 years and older 1, and are associated with 
high morbidity and mortality rates 2-4, disability, loss of quality of life, and institutionalization 
5-8. Furthermore, fall-related injuries place a substantial burden on healthcare systems due to 
the large number of visits to Emergency Departments (ED), hospital admissions, and 
admissions to long-term care and rehabilitation facilities 6,9-12. In order to reduce the 
prevalence of falls, risk factors have been identified and documented 13-15, and a substantial 
number of falls-prevention trials has been published 1,16,17.   
The use of certain drugs, i.e. the so-called fall-risk increasing drugs (FRIDs) 18-21, 
which are mainly psychotropic and cardiovascular drugs, has been associated with increased 
risk of falls and related injuries 18,19,21,22.  Although FRIDs withdrawal is frequently 
incorporated  in multifactorial intervention programs and trials, evidence regarding overall 
FRID withdrawal as a single intervention is scarce 17,20,23-25.  
In the present study, we investigated the effect of a structured medication assessment 
including withdrawal of FRIDs versus ‘care as usual’ on reducing falls in community-
dwelling older men and women, who visited the ED after experiencing a fall 26.  
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METHODS 
 
Study population 
The IMPROveFALL study is a randomized, multicenter trial, assessing the effect of a 
structured medication assessment including withdrawal of FRIDs versus ‘care as usual’ as a 
method for falls reduction 26. Patients meeting the following inclusion criteria were eligible 
for enrolment: aged 65 years or older, visited the ED of a participating hospital because of a 
fall, use of one or more fall-risk increasing drugs 18,19,21,26 (Table 1), Mini-Mental State 
Examination (MMSE) score of at least 21 out of 30 points 27,28, ability to walk 6 meters 
independently without assistive devices, and community dwelling. Participating hospitals 
included two academic and four regional hospitals in the Netherlands. Enrolment started in 
October 2008 and was completed in October 2011. The follow-up period was 12 months. The 
study was performed in accordance with the Declaration of Helsinki and all participants gave 
written informed consent. The local Medical Research Ethics Committees in all participating 
hospitals approved the study protocol.  
 
Covariates 
All persons visiting the ED because of a fall received care as usual for their injuries. 
Following the ED visit, patients were contacted by telephone. Subsequently, eligible and 
interested potential study participants received an appointment for the research outpatient 
clinic (OPC). The visits to the research OPC took place within two months after the fall-
related ED visit. If the patient met all eligibility criteria, the patient was asked to sign the 
Informed Consent Form. During the visit to the research OPC, a fall-related assessment was 
performed by the research physician. This included a falls history (a single faller was defined 
as someone who had fallen once in the 12 months preceding inclusion, a recurrent faller was 
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defined as someone who had fallen twice or more in the 12 months preceding inclusion), a 
fall-risk questionnaire 29. Medical history and medication use, including drug type, daily 
dose, frequency of use, and duration of use were registered. Collected data were verified with 
records from the patient’s general physician and local pharmacist. Furthermore, the 
assessment included a physical examination, physical performance tests, and a blood sample. 
The blood sample was used for measuring 25-hydroxyvitamin D levels, and to screen for 
hematologic, electrolyte, and liver and kidney function abnormalities. During the baseline 
assessment and at the follow-up research OPC visit, participants completed questionnaires on 
generic Health Related Quality of Life (HRQoL). HRQoL was measured using the Dutch 
versions of the EuroQol five dimensions 30, and the Short Form-12 version 2 31, at baseline 
and at 12 months-follow-up. A detailed description of the study protocol can be found 
elsewhere 26. 
 
Randomization 
Participants were randomized to one of the treatment arms, the intervention group versus 
‘care as usual’, using a web-based variable block randomization program that was available 
24 hours a day. Randomization using the trial website was done by the research physician. A 
block randomization with a block size of 4 was used. Due to the nature of the intervention, 
participants, research physicians, and care-givers could not be blinded to group assignment. 
 
Intervention 
All participants received a structured medication assessment.  In the ‘care as usual’ group, the 
medication was not changed. In the intervention group, FRIDs were withdrawn where 
possible. The single intervention consisted of a systematic FRIDs assessment combined with 
FRIDs-withdrawal or modification, when safely possible. FRIDs, as defined in the 
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literature18-21,26, were discontinued, reduced or substituted with potentially safer drugs in the 
intervention group if deemed safely possible. A complete list of FRIDs, based on current 
literature, is shown in Table 1. For each drug, the research physician assessed whether the 
initial indication still existed. Proposed changes in medication were discussed with a senior 
geriatrician, and if necessary with the prescribing physician. The participant’s General 
Practitioner (GP), and the prescribing physician if other than the GP were informed of any 
changes in medication. For each drug modification, the research physician followed the 
standardized instructions of the Dutch National Formulary 32, and a clinical pharmacologist 
was available for advice when needed. A research nurse offered counselling, evaluated 
possible negative effects via a standardized telephone follow-up, and discussed any problems 
regarding the drug modification with the research physician and geriatrician. 
All participants with follow-up were included in the intention-to-treat analyses. 
Regarding the per protocol analyses, the intervention group included both participants in 
whom FRID withdrawal/substitution was successful and participants in whom FRID 
withdrawal was not necessary or safely possible. In the event of more than one attempted 
FRID withdrawal, the successful withdrawal/substitution of at least one FRID was considered 
successful. The control group only included the participants in the “care as usual” group in 
whom we did not withdraw/substitute FRIDs during the first research OPC visit. 
 
Definition and measurement of falls  
A fall was defined as coming to rest unintentionally on the ground or a lower level with or 
without losing consciousness, but not induced by acute medical conditions, e.g., stroke, or 
exogenous factors such as a traffic accident 33. The history of falls was ascertained during a 
structured interview with the use of a falls questionnaire 29.  
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All participants received a Falls Calendar for reporting falls during a one-year follow-
up period. Falls were recorded weekly on the Falls Calendars, which had to be returned every 
three months. The first GP consultation and first ED visit because of a fall were also collected 
from abovementioned Falls Calendars and medical records. Follow-up started two weeks 
after completed intervention or two weeks after initial research OPC visit when no 
intervention was performed.  
 
Laboratory values 
Non-fasting blood samples were collected at the baseline assessment. Vitamin D deficiency 
was defined as serum 25(OH)D < 50 nmol/l 34,35. Anaemia was defined as haemoglobin 
levels < 8.1 mmol/L for men and < 7.5 mmol/L for women. 
  
Statistical analyses  
All analyses were performed using the Statistical Package of the Social Sciences (SPSS 
version 17.0, Chicago, Ill.). A p-value of < 0.05 was used as threshold for statistical 
significance.  
After sample size calculations, our aim was to include a total number of 620 
participants in the study, 310 in the control group and 310 in the intervention group 26. 
Calculation of the required sample size was based on the assumption that the annual 
cumulative incidence of further falling is 50% without intervention 36, a 15% drop-out rate 
(including death) 1, drug withdrawal being possible in 50% of the participants in the 
intervention group and a 50% decrease of further falls among participants with successful 
withdrawal 24. A single-sided test with an alpha level of 0.05 and a beta of 0.2 indicated that 
310 patients in each group would be sufficient in order to detect a 25% decrease of 
participants reporting further falls in the intervention group 26. 
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Data were analyzed according to the intention-to-treat principle (primary), and per-
protocol (secondary). The per-protocol analysis only included participants without a protocol 
violation as mentioned above. The hazard ratios for falling were calculated using a Cox-
regression model. Herein, the time between the start of follow-up and the first fall served as 
the primary outcome measure. The time between the start of follow-up and the second fall, 
first GP consultation and first ED visit because of a fall were also analyzed. Differences in 
cumulative incidence of falls, GP consultations and ED visit were analyzed using Poisson 
regression, adjusted for overdispersion because of interdependence among the dependent 
variable (falls). Subgroup analyses were performed, assessing the separate effect of 
cardiovascular and psychotropic drug withdrawal.  
Predefined models were constructed in order to adjust for age, gender and other 
potential confounders. Potential predefined confounders that were considered for inclusion in 
the multivariate model were MMSE, BMI, the Charlson Comorbidity index, vitamin D 
deficiency, anemia HRQoL, physical performance, number of drugs, the number of FRIDs, 
smoking, alcohol intake, history of recurrent falls, use of walking aid, urinary incontinence, 
vision problems, fear of falling, and dizziness. Confounders that led to a change in the 
regression coefficient (B) of 10% or more were retained in the multivariate-adjusted 
regression model. 
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RESULTS 
 
In total, 7,081 ED visitors were screened for possible trial participants, of whom 3,294 were 
not eligible, and 1,954 refused to participate. Subsequently, 612 participants were 
randomized in the IMPROveFALL study (Figure 1). Randomization resulted in 293 
participants being allocated to the control group and 319 participants to the intervention 
group (Figure 1). For the intention-to-treat analyses, 21 participants in the control group and 
11 participants in the intervention group were excluded due to withdrawal from study or 
death. For the per protocol  analyses, 9 participants in the control group and 66 participants in 
the intervention group were excluded due to protocol violations (Figure 1).  
The mean age of participants was 76 years, and 62% of the study population was 
female. No differences in baseline characteristics were noted between the intervention and 
control group (Table 2). The mean number of drugs and FRIDs used at baseline were six ± 
three and four ± two, respectively. Figure 2 (and supplementary eTable 1) specifies number 
of participants compliant to attempted interventions according to FRID categories; the 
supplementary eTable 1 includes the specific drug types. Participants using multiple types of 
FRIDs, e.g. psychotropic and cardiovascular FRIDs, are presented in both categories.  
Notably, in 40% of all FRIDs, 62% of cardiovascular FRIDs, 32% of psychotropic FRIDs, 
and 78% of other FRIDs, an intervention was not deemed possible or necessary. Of all 
attempted FRID-withdrawals 35% failed (37% of cardiovascular FRID interventions, 48% of 
psychotropic FRID interventions, and 31% of other FRID interventions), either due to non-
compliance or due to a return of the primary reason for which the drug had initially been 
prescribed.  
The percentage of participants using ≥ 3 FRIDs at baseline was 72% in the control 
group and 70% in the intervention group; these percentages did not decrease after 1 year 
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follow-up, 75% and 70% respectively (Figure 3). Furthermore, 66 participants (22%) in the 
intervention group and 68 (25%) in the control group used a higher number of FRIDs after 12 
months of follow-up than they used at baseline (Supplementary eTable 2), due to new 
prescriptions of FRIDs during the follow-up year. 
The number of participants in the control group (n=91; 34%) and intervention group 
(n=115; 37%) experiencing a fall during the one-year follow-up did not differ significantly (p 
= 0.33). Similarly, the number of participants in the control group (n=38; 14%) and 
intervention group (n=50; 16%) experiencing a recurrent fall during the one-year follow-up 
did not differ significantly (p = 0.45). The number of fallers requiring a GP consultation 
(n=46; 17% vs. 36; 12%, p=0.07) or ED visit (n=21; 8% vs. 16; 5%, p=0.22) did not differ 
significantly.  
The mean number of falls during follow-up in the control group was 0.83 and the 
mean number of falls in the intervention group was 0.80 (p = 0.88). The mean number of GP 
consultations because of a fall were 0.21 and 0.16 respectively, p=0.25; and the mean number 
of ED visits because of a fall were 0.08 and 0.06 respectively, p=0.51. 
In the intention-to-treat analysis, cox-regression analyses adjusted for age and gender 
showed that FRIDs withdrawal had no significant effect on the time to first fall (hazard ratio 
[HR] 1.17; 95% confidence interval [CI] 0.89-1.54), or on the time to the second fall (HR 
1.19; 95% CI 0.78-1.82) (Table 3). Similarly, no significant effect on the time to the first GP 
consultation because of a fall (HR 0.66; 95% CI 0.42-1.06) or the time to the first ED visit 
because of a fall (HR 0.85; 95% CI 0.43-1.68) was found (Table 3). Subgroup analyses of 
cardiovascular and psychotropic FRIDs withdrawal were similar, except for a significantly 
increased time until the first GP consultation because of a fall after cardiovascular FRIDs 
withdrawal (HR 0.57; 95% CI 0.34-0.93). The per-protocol analyses did not alter the results. 
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Poisson regression analyses showed FRIDs withdrawal did not have a significant 
effect on the cumulative incidence of falls (β -0.05; 95% confidence interval [CI] -0.52-  
0.42), or on the cumulative incidence of GP consultations (β -0.28; 95% CI -0.75- 0.18) or 
ED visits (β -0.22; 95% CI -0.88- 0.44) because of a fall. Subgroup analyses of 
cardiovascular and psychotropic FRIDs withdrawal were again similar, and per protocol 
analyses did not alter these results (Supplementary eTable 3). 
During the 12-months follow-up, 28 participants in the control group and 27 
participants in the intervention group sustained an injurious fall (p = 0.64). Seven participants 
in the control group and six participants in the intervention group sustained a fracture because 
of a fall (p = 0.66). Two participants, both in the control group, sustained a traumatic brain 
injury because of a fall (p = 0.14).  
Six participants died in the control group, causes were a ruptured coronary artery 
during a coronary angiography [1], kidney failure [1], oesophageal cancer [1], leukaemia [1], 
motor vehicle collision [1], and unknown [1]. Thirteen participants died in the intervention 
group, causes were sepsis [4], cancer [3], cerebrovascular accident [2], encephalopathy [1], 
heart failure [1], and unknown [2] (p = 0.15). Looking at the separate causes of death the 
distribution of these deaths appear to be coincidental and not due to adverse effects of drug 
withdrawal.  
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DISCUSSION 
 
In the present randomized controlled trial we found that a structured medication assessment 
including withdrawal of FRIDs as a single intervention did not lead to a reduction of further 
falls in community dwelling elderly who visited the ED because of a fall. In the intervention 
group, 35% of all attempted FRID-withdrawals failed, and at one year follow-up the 
percentage of participants using ≥ 3 FRIDs remained at 70%. Moreover, 22% of the 
participants used a higher number of FRIDs after 12 months of follow-up than they used at 
baseline. This indicates that FRID withdrawal or modification is difficult to maintain over 
one year, in a population of complex, multimorbid older fallers.  
There are several possible explanations for our main findings. First, in the last decade, 
falls prevention guidelines including instructions on fall-risk increasing drugs, and drug 
withdrawal- have been incorporated into usual care in the Netherlands, this may well have 
blunted the effect of the intervention. Second, in our intervention group a large proportion of 
FRIDs was prescribed adequately and thus withdrawal was not appropriate. Third, a large 
proportion of the participants in the intervention group was not compliant with the 
intervention, especially concerning psychotropic drugs withdrawal. Finally, when analyzing 
the participants in the successful withdrawal group individually, it was apparent that even 
when one or more FRIDs were successfully withdrawn, reduced, or substituted, several 
participants were prescribed additional FRIDs during the follow-up year by their GP or other 
specialist, often for new conditions.  
Our results are in contrast with previous studies, where the withdrawal of FRIDs has 
been shown to be safely possible and effective 20,23-25.  These studies, however, used different 
intervention approaches. In a study by Pit et al. the intervention was carried out by the 
participants’ GP, thereby probably increasing and sustaining the number of successful 
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withdrawals due to the more substantial doctor-patient relationship 25. Campbell et al. 
performed a psychotropic drug withdrawal intervention that was complete and double-
blinded, demonstrating the effectiveness of total psychotropic drug withdrawal on preventing 
falls in the short term (44 weeks) 24. However, as in our study, compliance was difficult to 
maintain.  
In our study, we observed a tendency towards fewer fall-related GP-visits in the 
intervention group, which was significant in the cardiovascular-drug withdrawal subgroup. 
Most studies associate psychotropic drugs with a greater fall risk 19,21, however, a greater fall-
risk reduction after withdrawal of cardiovascular drugs has been reported before 20. 
Furthermore, a recent large study found that antihypertensive medications were associated 
with an increased risk of serious fall injuries 37.  
A major strength of this study is that current recommendations regarding falls 
prevention studies were followed 38, i.e., addressing a single intervention in a randomized 
controlled trial. Furthermore, participants included were high-risk fallers, i.e., older men and 
women who visited the ED because of a fall. In this target group even a small reduction of 
their fall risk might prevent loss of independence. However, the following limitations should 
be taken into account when interpreting our results. First, recruiting participants proved 
challenging, the recruitment-period lasted 4 years despite enrolling 6 hospitals. Possible 
reasons for refusing to participate have been reported previously 39. Most common reasons 
for refusal were the added burden of additional visits to the hospital; highly independent older 
adults feeling “too healthy”; and personal opinions regarding the cause of the fall. Second, 
possibly the method of reporting falls was not as accurate as anticipated; as mentioned above, 
the intervention group reported as many falls as the control group, but the numbers of 
healthcare visits because of a fall (which were verified with GP records) were higher in the 
control group. Possibly fall incidence is better monitored with weekly phone calls instead of 
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self-report calendars 40. Third, as mentioned before, in the intervention group compliance 
with FRIDs withdrawal was limited. This might be improved if  the prescribing physician 
performs the withdrawal, as was the case in the study by Pit et al. 25. Further research into the 
method of implementation of the intervention is warranted, e.g. in a setting with a more 
substantial doctor-patient relationship. 
We found that withdrawal or modification of FRIDs in our study population was often 
not successful. Non-compliance was a significant factor; this may have affected our outcome, 
but also mirrors clinical practice. In this population of complex multimorbid patients visiting 
an ED because of a fall our single intervention approach of FRIDs-withdrawal was not 
effective in reducing falls.  
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FIGURES & TABLES 
 
Figure 1. Flowchart of study participants 
 
*Of the participants that died during follow-up, most were included in the analyses, except 
for two in the usual care and one in the intervention group.  
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Table 1. Fall-risk increasing drugs  
Drug category Drug type Therapeutic subgroups ATC code 
Psychotropic  Analgesics  Opioids N02A 
 Anti-epileptic Barbiturates, fatty-acid 
derivatives, carboxamide 
derivatives, other 
N03 
 Anti-Parkinson Dopaminergics, 
anticholenergics 
N04 
 Neuroleptics Dopamine D2-receptor 
agonists and serotonin 
dopamine receptor antagonists      
N05A 
 Anxiolytics & 
Sedative/Hypnotics  
Benzodiazepines and others N05B 
N05C 
Antidepressants Tricyclic antidepressants, 
selective serotonin reuptake 
inhibitors, serotonin-
norepinephrine reuptake 
inhibitors and monoamine 
oxidase inhibitors 
N06 
Other Anti-vertigo agents N07CA 
Cardiovascular  Cardiac therapy Digitalis, anti-arrhythmics, 
nitrates 
C01 
Anti-hypertensives Alpha-adrenoceptor blockers, 
centrally acting 
antihypertensives 
C02 
Diuretics Thiazide diuretics, loop 
diuretics 
C03 
Beta-blockers  C07 
Calcium-channel 
blockers 
 C08 
ACE/Angiotensin-II 
inhibitors 
 C09 
HMG CoA 
reductase inhibitors 
 C10AA 
Other drugs Gastro-Intestinal Anticholinergics A03AA 
  Hypoglycemics A10 
 Urogenital system α –blockers, spasmolytics G04BD 
G04CA 
 Anti-inflammatory Steroids  H02AB, R01AD 
  Non-steroidal anti-
inflammatory drugs (NSAID) 
B01AC06/08, 
M01A 
  Anti-gout  M04 
Muscle relaxant Hydroquinine M09AA 
Pulmonary Sympathomimetics, cough 
suppressants, anti-histaminics 
R03AC, R05DA, 
R06A 
*According to study protocol 26. ATC, Anatomical Therapeutic Chemical.  
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Table 2. Baseline characteristics 
 Control 
n = 293 
Intervention 
n = 319 
Demographics   
Age (year) 76.4 ± 6.6 76.5 ± 7.2 
Gender (female) 182 (62) 198 (62) 
MMSE 27.0 ± 2.4 27.0 ± 2.3 
BMI (m2/kg) 27.6 ± 4.7 27.6 ± 4.6 
Home care 69 (24) 82 (26) 
Fall risk factors   
Charlson Comorbidity Index 1.9 ± 1.6 1.9 ± 1.6 
Number of drugs 6.4 ± 3.3 6.3 ± 3.3 
Number of FRIDs 3.9 ± 2.0 3.9 ± 2.1 
History of recurrent falls 128 (44) 148 (46) 
Use of walking aid  72 (27) 78 (27) 
Urinary incontinence 37 (13) 52 (16) 
Vision problems 85 (30) 98 (32) 
Nycturia 177 (60) 181 (57) 
Fear of falling 104 (36) 118 (37) 
Dizziness 75 (26) 102 (32) 
Indoor fall 107 (37) 148 (46) 
Smoking 37 (13) 34 (11) 
Alcohol intake (≥ 3 units/day) 33 (11) 34 (11) 
Functional status   
Activities of Daily Living 0.80 ± 4.5 0.80 ± 3.3 
Instrumental Activities of Daily Living 1.39 ± 5.4 1.37 ± 4.0 
Biochemical   
Vitamin D deficiency  119 (41) 135 (42) 
Anemia 34 (13) 58 (19) 
Continuous data are shown as mean values ± standard deviation, categorical data as number 
with percentage. MMSE, Mini-Mental State Examination; BMI, Body Mass Index; FRID, 
Fall-Risk Increasing Drugs. 
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Figure 2. Specification of attempted FRID withdrawals in intervention group 
 
Figure 2 illustrates the number and percentage of participants where FRIDs withdrawal was 
not necessary or safely possible*, the failed withdrawals and the successful withdrawals; 
according to FRID categories (All, cardiovascular, psychotropic and other FRIDs) in the 
intervention group. Participants using multiple types of FRIDs, e.g. psychotropic and 
cardiovascular FRIDs are presented in both categories. FRID: Fall-Risk Increasing Drugs. 
CARDIO: cardiovascular FRIDs. PSYCH: psychotropic FRIDs. OTHER: other FRIDs. Data 
are shown as percentage of participants.  
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Figure 3. Amount of FRIDs at baseline and follow-up  
 
Figure 3 illustrates the number FRIDs being used at baseline and follow-up by participants in 
the control and intervention groups. FRID: Fall-Risk Increasing Drugs. Data are shown as 
number and percentage of participants. 
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Table 3. Cox-regression analyses including subgroup analyses  
 Intention to treat Per protocol 
 HR 95% CI p-value HR 95% CI p-value 
All FRIDs       
First fall 1.17 0.89; 1.54 0.27 1.19 0.89; 1.60 0.24 
Second fall 1.19 0.78; 1.82 0.41 1.26 0.80; 1.99 0.31 
GP consultation 0.66 0.42; 1.06 0.09 0.61 0.37; 1.02 0.06 
ED visit 0.85 0.43; 1.68 0.64 0.78 0.37; 1.63 0.50 
Cardiovascular FRIDs       
First fall 1.10 0.82; 1.49 0.51 1.12 0.81; 1.54 0.49 
Second fall 1.21 0.78; 1.88 0.41 1.31 0.81; 2.12 0.27 
GP consultation 0.57 0.34; 0.93 0.03 0.52 0.30; 0.91 0.02 
ED visit 0.77 0.38; 1.58 0.48 0.68 0.31; 1.50 0.34 
Psychotropic FRIDs       
First fall 1.28 0.84; 1.94 0.26 1.44 0.91; 2.29 0.12 
Second fall 1.17 0.64; 2.15 0.60 1.37 0.71; 2.67 0.35 
GP consultation  0.74 0.37; 1.48 0.40 0.88 0.42; 1.85 0.74 
ED visit 0.78 0.28; 2.16 0.64 0.93 0.32; 2.69 0.89 
Adjusted for age and gender. FRID, fall-risk increasing drug. 
 
